A Target Occupancy Study With Ritlecitinib.

Phase 1 Completed 16 enrolled Pfizer

Non-randomizedParallel-groupOpen-labelBasic science

Summary

This is a phase 1, open label, two-arm study to assess target occupancy and functional inhibition of JAK3 and TEC kinases by Ritlecitinib in healthy adult participants

Timeline

Start: 2021-10-22
Primary completion: 2022-01-14
Completion: 2022-01-14

Publications

Saadeddin A, Purohit V, Huh Y, Wong M, Maulny A, Dowty ME, Sagawa K. Virtual Bioequivalence Assessment of Ritlecitinib Capsules with Incorporation of Observed Clinical Variability Using a Physiologically Based Pharmacokinetic Model. AAPS J. 2024 Jan 24;26(1):17. doi: 10.1208/s12248-024-00888-9.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ritlecitinib	Small molecule	50 mg	—
Subject	Ritlecitinib	Small molecule	200 mg	—

Indications

No indication recorded.